These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
330 related articles for article (PubMed ID: 30159775)
21. Use of proton pump inhibitors and risk of osteoporosis-related fractures. Targownik LE; Lix LM; Metge CJ; Prior HJ; Leung S; Leslie WD CMAJ; 2008 Aug; 179(4):319-26. PubMed ID: 18695179 [TBL] [Abstract][Full Text] [Related]
22. Proton Pump Inhibitors, Histamine-2 Receptor Antagonists, and Hip Fracture Risk among Patients on Hemodialysis. Vangala C; Niu J; Lenihan CR; Mitch WE; Navaneethan SD; Winkelmayer WC Clin J Am Soc Nephrol; 2018 Oct; 13(10):1534-1541. PubMed ID: 30262672 [TBL] [Abstract][Full Text] [Related]
23. Are proton pump inhibitors associated with the development of community-acquired pneumonia? A meta-analysis. Giuliano C; Wilhelm SM; Kale-Pradhan PB Expert Rev Clin Pharmacol; 2012 May; 5(3):337-44. PubMed ID: 22697595 [TBL] [Abstract][Full Text] [Related]
24. Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study. Pouwels S; Lalmohamed A; Souverein P; Cooper C; Veldt BJ; Leufkens HG; de Boer A; van Staa T; de Vries F Osteoporos Int; 2011 Mar; 22(3):903-10. PubMed ID: 20585937 [TBL] [Abstract][Full Text] [Related]
25. A population-based case-control study: proton pump inhibition and risk of hip fracture by use of bisphosphonate. Lee J; Youn K; Choi NK; Lee JH; Kang D; Song HJ; Park BJ J Gastroenterol; 2013 Sep; 48(9):1016-22. PubMed ID: 23307040 [TBL] [Abstract][Full Text] [Related]
26. Proton pump inhibitors therapy and risk of Clostridium difficile infection: Systematic review and meta-analysis. Trifan A; Stanciu C; Girleanu I; Stoica OC; Singeap AM; Maxim R; Chiriac SA; Ciobica A; Boiculese L World J Gastroenterol; 2017 Sep; 23(35):6500-6515. PubMed ID: 29085200 [TBL] [Abstract][Full Text] [Related]
27. Study of the association between hip fracture and acid-suppressive drug use in a UK primary care setting. Cea Soriano L; Ruigómez A; Johansson S; García Rodríguez LA Pharmacotherapy; 2014 Jun; 34(6):570-81. PubMed ID: 24634193 [TBL] [Abstract][Full Text] [Related]
28. Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies. Yu EW; Bauer SR; Bain PA; Bauer DC Am J Med; 2011 Jun; 124(6):519-26. PubMed ID: 21605729 [TBL] [Abstract][Full Text] [Related]
29. Proton pump inhibitor use and risk of hip fractures among community-dwelling persons with Alzheimer's disease-a nested case-control study. Torvinen-Kiiskinen S; Tolppanen AM; Koponen M; Tanskanen A; Tiihonen J; Hartikainen S; Taipale H Aliment Pharmacol Ther; 2018 Apr; 47(8):1135-1142. PubMed ID: 29508411 [TBL] [Abstract][Full Text] [Related]
31. Proton Pump Inhibitors and Fracture Risk: A Review of Current Evidence and Mechanisms Involved. Thong BKS; Ima-Nirwana S; Chin KY Int J Environ Res Public Health; 2019 May; 16(9):. PubMed ID: 31060319 [TBL] [Abstract][Full Text] [Related]
32. Adverse outcomes of long-term use of proton pump inhibitors: a systematic review and meta-analysis. Islam MM; Poly TN; Walther BA; Dubey NK; Anggraini Ningrum DN; Shabbir SA; Jack Li YC Eur J Gastroenterol Hepatol; 2018 Dec; 30(12):1395-1405. PubMed ID: 30028775 [TBL] [Abstract][Full Text] [Related]
33. Proton pump inhibitor use and fracture risk - effect modification by histamine H1 receptor blockade. Observational case-control study using National Prescription Data. Abrahamsen B; Vestergaard P Bone; 2013 Nov; 57(1):269-71. PubMed ID: 23973557 [TBL] [Abstract][Full Text] [Related]
34. Use of proton pump inhibitors increased the risk of hip fracture: a population-based case-control study. Chiu HF; Huang YW; Chang CC; Yang CY Pharmacoepidemiol Drug Saf; 2010 Nov; 19(11):1131-6. PubMed ID: 20872906 [TBL] [Abstract][Full Text] [Related]
35. Association of proton pump inhibitors with risk of hepatic encephalopathy in advanced liver disease: A meta-analysis. Tantai XX; Yang LB; Wei ZC; Xiao CL; Chen LR; Wang JH; Liu N World J Gastroenterol; 2019 Jun; 25(21):2683-2698. PubMed ID: 31210719 [TBL] [Abstract][Full Text] [Related]
36. Association Between Calcium or Vitamin D Supplementation and Fracture Incidence in Community-Dwelling Older Adults: A Systematic Review and Meta-analysis. Zhao JG; Zeng XT; Wang J; Liu L JAMA; 2017 Dec; 318(24):2466-2482. PubMed ID: 29279934 [TBL] [Abstract][Full Text] [Related]
37. Proton pump inhibitor use and risk of dementia: Systematic review and meta-analysis. Li M; Luo Z; Yu S; Tang Z Medicine (Baltimore); 2019 Feb; 98(7):e14422. PubMed ID: 30762748 [TBL] [Abstract][Full Text] [Related]
38. Use of proton pump inhibitors and mortality after hip fracture in a nationwide study. Brozek W; Reichardt B; Zwerina J; Dimai HP; Klaushofer K; Zwettler E Osteoporos Int; 2017 May; 28(5):1587-1595. PubMed ID: 28083667 [TBL] [Abstract][Full Text] [Related]
39. Proton pump-inhibiting drugs, calcium homeostasis, and bone health. Wright MJ; Proctor DD; Insogna KL; Kerstetter JE Nutr Rev; 2008 Feb; 66(2):103-8. PubMed ID: 18254877 [TBL] [Abstract][Full Text] [Related]
40. Proton pump inhibitor use and the antifracture efficacy of alendronate. Abrahamsen B; Eiken P; Eastell R Arch Intern Med; 2011 Jun; 171(11):998-1004. PubMed ID: 21321287 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]